Suddenly, the Bristol-Celgene deal is looking shaky. What's next?
W happened to Celgene (CELG) at the proposed $ 74 billion acquisition by Bristol-Myers Squibb (BMY) dies
"That would be a total nightmare, a worst-case scenario for Celgene, so right now, the directors on his board are doing everything they can to prevent the deal from unraveling, ”said Jason Aryeh, founder and partner at JALAA Equities, an activist hedge fund.
What is it?
Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
Senior Writer, Biotech
Adam is STAT's national biotech columnist, reporting on the intersection of biotech and Wall Street.